We are pleased to share with you that we have formed a strategic manufacturing collaboration with University of Pennsylvania’s Gene Therapy Program.  The collaboration will combine Penn’s significant expertise in viral vector production developed over 20 years with the manufacturing expertise and infrastructure of WuXi.  Scientists from Penn will work with WuXi to establish efficient, scalable manufacturing processes within cGMP guidelines for the production of viral vectors at WuXi’s 145,000 square-foot state-of-the-art manufacturing facility under construction at Navy Yard in Philadelphia.

We are delighted to partner with University of Pennsylvania to provide an integrated solution for cGMP viral vector manufacturing to advance the many exciting clinical programs underway.  The ability to deploy advanced analytical tools, an ongoing technical collaboration, and application of the knowhow developed at Penn and in Dr. Jim Wilson’s laboratory will be particularly valuable as we expand our clinical and commercial manufacturing of AAV vectors here in Philadelphia.

Related Links:

REGENXBIO and WuXi Collaborate on Gene Therapy Manufacturing